Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gerard Falgoust

Internal Medicine Plaquemine, LA Medical Doctor

NPI 1720167869 CMS profile 611389

59355 River West Dr, Landmark Of Plaquemine LLC, Plaquemine, LA 70764

Open in the dashboard

General payments

$2,790

169 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gerard Falgoust of Plaquemine, LA is reported in the CMS Open Payments database as having received $2,790 across 169 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 83rd percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $172 10
2024 General $540 34
2023 General $727 46
2022 General $677 36
2021 General $194 11
2020 General $48 3
2019 General $431 29

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gerard Falgoust
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Gerard Falgoust were reported at $172. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Gerard Falgoust Internal Medicine median Middle half National median
2019 $431 $159 $48–$570 $163
2020 $48 $119 $33–$402 $114
2021 $194 $135 $37–$521 $132
2022 $677 $141 $42–$496 $149
2023 $727 $149 $45–$519 $160
2024 $540 $154 $47–$537 $164
2025 $172 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $564 45 payments
  2. Teva Pharmaceuticals USA, Inc. $413 14 payments
  3. Novo Nordisk Inc $267 17 payments
  4. Otsuka America Pharmaceutical, Inc. $209 13 payments
  5. Lilly USA, LLC $161 10 payments
  6. Lundbeck LLC $147 7 payments
  7. Amarin Pharma Inc. $110 6 payments
  8. AstraZeneca Pharmaceuticals LP $109 7 payments
  9. Pfizer Inc. $101 5 payments
  10. Abbott Laboratories $87 4 payments
  11. Other $622 41 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,672 167 payments
  2. Education $118 2 payments
Products named General payments · program years 2019–2025
  1. AUSTEDO $294 11 payments
  2. UBRELVY $279 25 payments
  3. Ozempic $267 17 payments
  4. RYBELSUS $197 13 payments
  5. QULIPTA $181 13 payments
  6. REXULTI Psychiatry $147 7 payments
  7. VRAYLAR $144 11 payments
  8. REXULTI Psychiatry $120 7 payments
  9. MOUNJARO $109 6 payments
  10. Vascepa $93 5 payments
  11. Other $1,538 98 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 264 drugs

Part D claims

22,380

Median for Internal Medicine: 777

Drug cost

$2,738,620

Median for Internal Medicine: $73,373

Branded share of claims

22.5%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ingrezza Valbenazine Tosylate Brand 201 $791,894
Eliquis Apixaban Brand 496 $188,405
Ozempic Semaglutide Brand 137 $178,028
Jardiance Empagliflozin Brand 328 $148,227
Invega Sustenna Paliperidone Palmitate Brand 41 $123,557
Mounjaro Tirzepatide Brand 90 $112,199
Santyl Collagenase Clostridium Hist. Brand 36 $82,580
Biktarvy Bictegrav/Emtricit/Tenofov Ala Brand 17 $71,651
Austedo Deutetrabenazine Brand 24 $64,965
Trulicity Dulaglutide Brand 39 $51,444

The 10 drugs with the highest cost, of 264 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$65,034

Of which drugs: $3,764

Medicare patients

330

Average age 71

Services billed

1,245

149 women, 181 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Depression 61%
Diabetes 44%
Arthritis 43%
Alzheimer's or dementia 33%
Ischemic heart disease 31%
Chronic kidney disease 31%
COPD 29%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 17 19 $1,535
Injection, dexamethasone sodium phosphate, 1 mg J1100 Office 18 168 $9

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 14 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
REXULTI
  • Lundbeck LLC $101
  • Otsuka America Pharmaceutical, Inc. $19
$120 14 —
UBRELVY
  • AbbVie, Inc. $67
$67 — —
VOQUEZNA
  • Phathom Pharmaceuticals, Inc. $57
$57 — —
MOUNJARO
  • Lilly USA, LLC $39
$39 90 —
QULIPTA
  • AbbVie, Inc. $35
$35 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 14 in the dashboard with a free account

Records

169 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record